of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, ad…

Termination of a Material Definitive Agreement On October 19, 2026, in connection with the entry into the Credit Agreement, the Company used a portion of the proceeds of the borrowings under the Credit Agreement and the offering of the Notes to repay in full all outstanding term loans and revolving loans, together with accrued and unpaid interest and fees, under its Seventh Amended and Restated Credit Agreement, dated as of March 24, 2023 (as amended by Amendment No. 1, dated as of June 6, 20…

Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant The information set forth in

Regulation FD Disclosure On October 19, 2026, the Company issued a press release announcing the closing of the Credit Agreement and Notes offering. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of such section, nor shall it be…

Entry Into a Material Definitive Agreement On October 19, 2026, Integra LifeSciences Holdings Corporation (the “Company”) entered into an amended and restated credit agreement with a syndicate of lending banks, and Bank of America, N.A., as Administrative Agent, Swing Line Lender and a L/C Issuer (the “Credit Agreement”). In addition, on October 19, 2026 the Company completed a private unregistered offering of $450 million aggregate principal amount of its 9.500% Senior Secured Notes due 2033…

Regulation FD Disclosure On October 9, 2026, Integra LifeSciences Holdings Corporation (the “Company”) issued a press release announcing the pricing of $450 million aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”) in a private placement. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The Company expects that the interest rate on the Notes, together with the anticipated interest rates on other elements of the Company…

Results of Operations and Financial Condition. Preliminary Unaudited Results for the Third Quarter On October 2, 2026, Integra LifeSciences Holdings Corporation (the “Company”) announced certain preliminary unaudited results for the third quarter ended September 30, 2026. The Company expects its reported revenue to be between $410 million to $412 million, reflecting an estimated $7 million impact of flooding-related supply disruptions on the Company’s manufacturing facility in Cincinnati, Ohi…

Regulation FD Disclosure. Integra LifeSciences Holdings Corporation (the “Company”) hereby furnishes the updated investor presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company may use, from time to time, in presentations to existing or prospective lenders in connection with the Company’s previously-disclosed plans to refinance its outstanding senior credit facility in 2026. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “fi…

of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, ad…

The filing pertains to a stockholder-approved equity incentive plan amendment, not a management change.

of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, ad…

President and Chief Executive Officer — Dr. Stuart M. Essig: Dr. Stuart Essig was appointed as President and Chief Executive Officer, succeeding Mojdeh Poul.

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT As previously disclosed, on December 18, 2018, certain subsidiaries of Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), entered into a $150 million accounts receivable securitization facility (the “A/R Facility”) to reduce outstanding revolving borrowings under the Company’s senior credit facility and to provide additional liquidity and funding for the ongoing business needs of the Company and its subsidiaries. The d…

of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, ad…

CFO — Lea Knight: The filing discloses the adoption of a change in control severance program, which is a compensatory arrangement rather than an actual departure or appointment of an executive.

of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, ad…

of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, ad…

Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information set forth under

Entry Into a Material Definitive Agreement On June 6, 2025, Integra LifeSciences Holdings Corporation (the “Company”) entered into an amendment (the “Amendment”) to the Seventh Amended and Restated Credit Agreement, dated as of March 24, 2023, among the Company, a syndicate of lending banks, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Citibank N.A., JPMorgan Chase Bank, N.A., Morgan Stanley MUFG Loan Partners, LLC, PNC Bank, N.A., Truist Bank and Wells Fa…

The filing discloses the approval of an equity incentive plan amendment, which is a compensatory arrangement rather than a change in management or board composition.

of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, ad…

of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, ad…

CFO — Lea Knight: The filing discloses the adoption of a change in control severance program, which is a compensatory arrangement rather than an actual departure or appointment of an executive.

of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Discussion of Adjusted Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, or…

CEO — Mojdeh Poul: The filing announces the appointment of a new external candidate as President and CEO, which is a significant leadership change but not a departure of a sitting executive.